NO20025525D0 - Substituerte pyrrolpyridinonderivater, brukbare som fosfordiesterase-inhibitorer - Google Patents

Substituerte pyrrolpyridinonderivater, brukbare som fosfordiesterase-inhibitorer

Info

Publication number
NO20025525D0
NO20025525D0 NO20025525A NO20025525A NO20025525D0 NO 20025525 D0 NO20025525 D0 NO 20025525D0 NO 20025525 A NO20025525 A NO 20025525A NO 20025525 A NO20025525 A NO 20025525A NO 20025525 D0 NO20025525 D0 NO 20025525D0
Authority
NO
Norway
Prior art keywords
useful
substituted pyrrole
pyridinone derivatives
diesterase inhibitors
phosphorus
Prior art date
Application number
NO20025525A
Other languages
English (en)
Other versions
NO20025525L (no
NO324843B1 (no
Inventor
Zhihua Sui
Mark J Macielag
Jihua Guan
Weiqin Jiang
James C Lanter
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20025525D0 publication Critical patent/NO20025525D0/no
Publication of NO20025525L publication Critical patent/NO20025525L/no
Publication of NO324843B1 publication Critical patent/NO324843B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20025525A 2000-05-17 2002-11-18 Substituerte pyrrolpyridinonderivater nyttige som fosfordiesterase-inhibitorer, og farmasoytiske preparater som innbefatter slike NO324843B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20464600P 2000-05-17 2000-05-17
PCT/US2001/014391 WO2001087882A2 (en) 2000-05-17 2001-05-03 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

Publications (3)

Publication Number Publication Date
NO20025525D0 true NO20025525D0 (no) 2002-11-18
NO20025525L NO20025525L (no) 2003-01-03
NO324843B1 NO324843B1 (no) 2007-12-17

Family

ID=22758822

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025525A NO324843B1 (no) 2000-05-17 2002-11-18 Substituerte pyrrolpyridinonderivater nyttige som fosfordiesterase-inhibitorer, og farmasoytiske preparater som innbefatter slike

Country Status (29)

Country Link
US (3) US6635638B2 (no)
EP (1) EP1296981B1 (no)
JP (1) JP5366349B2 (no)
KR (2) KR100854050B1 (no)
CN (1) CN1280291C (no)
AR (1) AR028575A1 (no)
AT (1) ATE278690T1 (no)
AU (1) AU6117801A (no)
BG (1) BG65925B1 (no)
CA (1) CA2409743C (no)
CZ (1) CZ20023945A3 (no)
DE (1) DE60106252T2 (no)
ES (1) ES2230316T3 (no)
GE (1) GEP20053510B (no)
HK (1) HK1054034B (no)
HR (1) HRP20020911B1 (no)
HU (1) HUP0302226A3 (no)
IL (2) IL152872A0 (no)
MX (1) MXPA02011425A (no)
MY (1) MY126917A (no)
NO (1) NO324843B1 (no)
NZ (1) NZ522732A (no)
PL (1) PL363150A1 (no)
PT (1) PT1296981E (no)
RU (1) RU2267490C2 (no)
SK (1) SK286992B6 (no)
UA (1) UA72611C2 (no)
WO (1) WO2001087882A2 (no)
ZA (1) ZA200210114B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
WO2002064590A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
JP4223285B2 (ja) * 2001-02-12 2009-02-12 リリー アイコス リミテッド ライアビリティ カンパニー 化合物
CN1280292C (zh) * 2001-11-14 2006-10-18 奥索-麦克尼尔药品公司 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
ES2297217T3 (es) * 2002-06-19 2008-05-01 Janssen Pharmaceutica Nv Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa.
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
SG184755A1 (en) 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
JP2008531570A (ja) * 2005-02-25 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３−（ｒ）−３−（２，３−ジヒドロベンゾフラン−５−イル）−１，２，３，４−テトラヒドロピロロ［３，４−ｂ］キノリン−９−オンの有効かつ立体選択的大規模合成方法
WO2006093719A1 (en) * 2005-02-25 2006-09-08 Janssen Pharmaceutica, N.V. An efficient and stereoselective process for large scale synthesis of 3-(r)-3- (2,3-dihydrobenzofuran-5-yl)-1,2,3,4- tetrahydropyrrolo{3,4-b}quinolin-9-one
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
WO2013043553A1 (en) * 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP3160964B1 (en) 2014-06-27 2024-03-13 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
CN108752340B (zh) * 2018-07-18 2020-09-01 山东中医药大学附属医院 吡咯并喹啉衍生物及其在治疗心律失常中的用途
CN109134463B (zh) * 2018-09-17 2020-05-08 山东大学 β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US204646A (en) * 1878-06-04 Improvement in hat-brims
DE2023514A1 (de) 1970-05-14 1971-12-02 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 5,6-gamma-Pyridonderivaten
CH625521A5 (no) 1976-10-15 1981-09-30 Sandoz Ag
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1995029900A1 (en) 1994-04-29 1995-11-09 Takeda Chemical Industries, Ltd. CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CN1072219C (zh) 1995-06-01 2001-10-03 武田药品工业株式会社 二氮杂䓬酮、其生产和用途
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2792937B1 (fr) * 1999-04-27 2001-08-10 Cemaf NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази

Also Published As

Publication number Publication date
GEP20053510B (en) 2005-05-10
EP1296981A2 (en) 2003-04-02
RU2267490C2 (ru) 2006-01-10
HRP20020911A2 (en) 2004-12-31
EP1296981B1 (en) 2004-10-06
MY126917A (en) 2006-10-31
KR20020094063A (ko) 2002-12-16
AR028575A1 (es) 2003-05-14
CN1441801A (zh) 2003-09-10
NZ522732A (en) 2004-10-29
US20020010183A1 (en) 2002-01-24
SK17132002A3 (sk) 2003-12-02
ATE278690T1 (de) 2004-10-15
PT1296981E (pt) 2004-12-31
CN1280291C (zh) 2006-10-18
WO2001087882A3 (en) 2002-05-23
PL363150A1 (en) 2004-11-15
KR20030031483A (ko) 2003-04-21
HUP0302226A3 (en) 2012-12-28
IL152872A (en) 2010-11-30
ZA200210114B (en) 2004-03-12
KR100854050B1 (ko) 2008-08-26
MXPA02011425A (es) 2004-09-06
HUP0302226A2 (hu) 2003-11-28
BG107284A (bg) 2003-07-31
CZ20023945A3 (cs) 2003-10-15
DE60106252D1 (de) 2004-11-11
JP2003533524A (ja) 2003-11-11
UA72611C2 (uk) 2005-03-15
US20050113402A1 (en) 2005-05-26
WO2001087882A2 (en) 2001-11-22
ES2230316T3 (es) 2005-05-01
US20040044021A1 (en) 2004-03-04
CA2409743C (en) 2010-10-19
DE60106252T2 (de) 2006-03-02
BG65925B1 (bg) 2010-05-31
HK1054034B (zh) 2005-04-29
SK286992B6 (sk) 2009-09-07
NO20025525L (no) 2003-01-03
IL152872A0 (en) 2003-06-24
NO324843B1 (no) 2007-12-17
US6635638B2 (en) 2003-10-21
HRP20020911B1 (en) 2009-01-31
HK1054034A1 (en) 2003-11-14
JP5366349B2 (ja) 2013-12-11
AU6117801A (en) 2001-11-26
CA2409743A1 (en) 2001-11-22
US6818646B2 (en) 2004-11-16

Similar Documents

Publication Publication Date Title
NO20025525D0 (no) Substituerte pyrrolpyridinonderivater, brukbare som fosfordiesterase-inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20012701D0 (no) Aryl- og heterosyklylsubstituerte pyrimidinderivater som antikoagulanter
DK0946512T3 (da) 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20021695D0 (no) 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20021407L (no) Bifenylderivater anvendt som NHE-3-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1534707T5 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
DK1571140T3 (da) Substituerede C-cyjklohexylmethylamin-derivater
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE272045T1 (de) Substituierte 1-aminobutan-3-ol-derivate
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DK1390351T3 (da) Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DK1115708T3 (da) Aminoalkyl-3,4-dihydriquinolinderivater som NO-synthaseinhibitorer
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees